<DOC>
	<DOCNO>NCT02142725</DOCNO>
	<brief_summary>The purpose study compare two different dose regimen phosphatidylcholine versus placebo induction remission ulcerative colitis patient non-responsive standard mesalamine treatment .</brief_summary>
	<brief_title>Phosphatidylcholine ( LT-02 ) Induction Remission Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Established diagnosis ulcerative colitis Active ulcerative colitis disease extent â‰¥ 15 cm Active disease despite treatment mesalamine Crohn 's disease , indeterminate colitis , ischemic colitis , radiation colitis , microscopic colitis , diverticular disease associate colitis , Toxic megacolon fulminant colitis Colon resection Evidence infectious colitis Celiac disease Bleeding hemorrhoids History presence ischemic heart disease , myocardial infarction , peripheral arterial disease , ischemic stroke , transient ischemic attack Any severe concomitant renal , endocrine , psychiatric disorder Any relevant know systemic disease History cancer last five year Abnormal hepatic function liver cirrhosis Abnormal HbA1c screen visit Patients know hypersensitivity soy Known intolerance/hypersensitivity Investigational Medicinal Product ( IMP ) Treatment steroids/methotrexate/Tumor necrosis factoralphaantagonists/azathioprine/ 6mercaptopurine/antiintegrin/coumarins Treatment investigational drug Existing intend pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>